Marksans Pharma LtdNSE:MARKSANS
Current view Q4 2026
Makes cheap generic medicines sold to US and UK stores. Steadily grabbing more shelf space in America, debt-free with cash to spare; the new Goa factory is only half used, so room to grow.
Latest exchange filings last 5 · 5 after Q4 2026
- 17 Sep ’26SEBI special window opened for re-lodgment of pre-April 2019 physical share transfer requests until February 4, 2027. ↗
- 7 Sep ’26Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF ↗
- 1 Sep ’26Marksans Pharma will attend Ashwamedh-Elara India Dialogue 2026 investor meet on 2 September 2026 in Mumbai. ↗
- 27 Aug ’26Marksans Pharma AGM voting results announced; all resolutions passed, including 0.90 final dividend and Sandra Saldanha reappointment. ↗
- 27 Aug ’26Marksans Pharma’s 34th AGM resolutions passed; final dividend of Re.0.90 approved, along with director reappointments. ↗
Exchange filings, with the company's own one-line summary, read off the same page as the figures. Screener publishes only the most recent few, so this is the last 5 — not everything filed since your note, and a quiet-looking list is not proof of a quiet quarter. A filing is marked new when it is dated after the end of the quarter your note covers. Not scored, and not a judgement — a routine repayment notice and a takeover sit in the same list.
AI concall report · Q4 2026
The full earnings-call read behind this view — what management promised, what they delivered, and the earning trigger.
Growth Q4 2026
| Metric | This year vs lastYoY · vs Q4 2025 | vs the quarter beforeQoQ, sequential · vs Q3 2026 | 3-year yearly average3Y CAGR · compounded | 5-year yearly average5Y CAGR · compounded |
|---|---|---|---|---|
| Sales | ▲ +20.9% | +13.5% | +16.8% | +16.5% |
| Operating profit | ▲ +53.5% | +21.1% | +19.6% | +14.5% |
| EPS | ▲ +63.5% | +30.8% | +16.2% | +9.9% |
| PAT | ▲ +63.7% | +30.7% | — | — |
Tinted rows drive the Tier. Tier = the weaker of YoY Sales and YoY PAT growth. Here the weaker is Sales at +20.9%, which is ≥ 20% → Tier 1.
QoQ is sequential, not a trend. For most Indian companies the March quarter is seasonally the largest, so a June-quarter fall against it is a calendar effect. Only the YoY column feeds the Tier.
Multibagger potential
Good69/100
Growing fast — and the market has noticed. Profit per share grew 16% a year, and buyers now pay more for each rupee of it than they did a year ago. Some of the re-pricing has already happened.
₹332 → ₹663 needs the P/E at 46× — it is 36× today, and has ranged 16× to 119× over the last 5 years. The rest would come from earnings growing as they have.
What you pay for its profitlog scale · 5-year range
Tripling needs 69× — it has traded there — high was 119×.
At ₹340 the price-tag on its earnings reaches the 37× it is being projected toward — the point where being cheap against that yardstick is used up.
Both engines fired — but you're buying after the re-rate.
How this is calculated
This is arithmetic, not a forecast — Return = ΔEPS × ΔMultiple. It says what would have to be true, not how likely it is, and "earnings keep growing at this rate for three more years" is the assumption doing the most work. This is a mid-cap at ₹14,363 cr, so the odds of a re-rate are not fighting its own size.
Growth rate used: 16.2% — the weakest of EPS / Sales / Op-profit from 3-year EPS CAGR. Latest quarter reads 60%.
How it compares with its rivals Healthcare · 6 of 159 listed
These are the industry's largest names rather than companies of its own size, so the columns are worth reading straight across — a ranking against them would only be restating the size gap.
| Company | Price | P/E | Size | ROCE | Profitlast qtr | Saleslast qtr |
|---|---|---|---|---|---|---|
| Marksans Pharma | ₹320 | 28.0× | ₹14,479 Cr | 18.8% | +169.5% | +35.6% |
| Sun Pharma.Inds. | ₹1,853 | 35.1× | ₹4.45 L Cr | 20.5% | +6.0% | +10.5% |
| Divi's Lab. | ₹9,379 | 83.5× | ₹2.49 L Cr | 22.0% | +65.5% | +27.8% |
| Torrent Pharma. | ₹4,855 | 82.8× | ₹1.85 L Cr | 15.2% | +5.8% | +54.9% |
| Zydus Lifesci. | ₹1,152 | 23.6× | ₹1.15 L Cr | 21.1% | −35.1% | +22.0% |
| Cipla | ₹1,375 | 31.0× | ₹1.11 L Cr | 15.5% | −39.2% | +2.3% |
Screener's own peer group, from the request already made for the industry P/E. It serves the industry's largest names by market cap, not companies of a similar size, so treat this as context rather than a like-for-like table; this company is always shown. On a phone the price, size and sales columns are dropped rather than pushed off the edge. Not part of the score.
Business quality to Jun 2026
| Are the margins widening? | wider, but it has moved around a lot | operating margin 20% → 25% over 3 years |
|---|---|---|
| Did the profit turn into cash? | most of it, with some tied up | 99% last year, 79% over three · free cash flow ₹329 cr, positive in 5 of 5 years |
| Is the growth borrowed? | lightly borrowed | ₹343 cr — 0.11× its own equity (was 0.13×) |
| Is it being collected? | collection is steady | 80 days to collect, up 5 in a year · cash cycle 261 days |
| Who has been buying? | the promoters have held steady | promoters 43.9%, 43.9% → 43.9% over 2.8 years · FIIs 17.5% (−2.4) · DIIs 6.2% (+0.7) · shareholders 2,07,937 → 2,46,635 |
| What does it earn on its capital? | earns a fair return on its capital | ROCE 18.8% · ROE 15.2% |
Fetched from the filings, not typed — and deliberately not part of the score. These are the questions the score cannot ask: it reads growth, price and trend, so a company can score well while its profit never becomes cash. Weigh these beside the note, not against the number.